# GSK gains priority FDA review for Jemperli in rectal cancer

- Link: https://www.directorstalkinterviews.com/gsk-gains-priority-fda-review-for-jemperli-in-rectal-cancer/4121260898
- Published: 2026-08-24T07:21:45+01:00
- Author: Ethan Davis

GSK** Plc** ([LON:GSK](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l))
today announced the US Food and Drug Administration (FDA) has accepted for priority
review a supplemental Biologics License Application (sBLA) for Jemperli (dostarlimab)
for patients with previously untreated stage II and III mismatch repair deficient(
dMMR)/microsatellite instability-high (MSI-H) locally advanced rectal cancer. The
FDA has assigned a PDUFA action date of February 2027. The application is also eligible
for expedited review through the National Priority Voucher program, which could 
result in an earlier FDA decision^(1).

Rectal cancer, a type of bowel cancer, affects around 770,000 people globally each
year^(2) and approximately 5-10% of cases have the dMMR/MSI-H subtype^(3). Chemotherapy,
radiation and surgery are the standard of care and while often effective, they can
have lasting adverse effects on bowel, urinary and sexual function, fertility and
overall quality of life^(4,5,6).

The application is based on positive data from the registrational phase II, single-
arm AZUR-1 trial, which met its primary objective by demonstrating a meaningful 
and sustained clinical complete response rate for 12 months (cCR12) with no detectable
signs of cancer for at least one year. In interim data, the safety and tolerability
profile of dostarlimab was generally consistent with its well-characterised and 
manageable safety profile observed across solid tumours. These data will be submitted
for presentation at a scientific congress later in 2026.

AZUR-1 results represent a substantial improvement compared to the historical standard
of care^(7). The data support the potential for dostarlimab, if approved, to become
the first immunotherapy capable of eliminating or delaying the need for chemotherapy,
radiation and surgery for some patients in this population. These findings build
on earlier research conducted with Memorial Sloan Kettering Cancer Center (MSK),
which first demonstrated the potential for dostarlimab to achieve clinical complete
responses without other treatments in patients with dMMR/MSI-H locally advanced 
rectal cancer.

Dostarlimab was previously granted Fast Track and Breakthrough Therapy Designations
in this setting^(8,9). The application has also been accepted under Project Orbis,
an FDA Oncology Center of Excellence initiative that enables coordinated reviews
by international health authorities and may support earlier regulatory decisions
and patient access. Regulatory decisions remain independent in each country.

**References**

1. FDA press release issued 6 November, 2025. FDA Awards Second Batch of National
Priority Vouchers. Available at https://www.fda.gov/news-events/press-announcements/
fda-awards-second-batch-national-priority-vouchers

2. International Agency for Research on Cancer (IARC) (2024) Rectum cancer fact 
sheet: GLOBOCAN 2022. World Health Organization. Available at: https://gco.iarc.
who.int/media/globocan/factsheets/cancers/9-rectum-fact-sheet.pdf. Accessed August
2026

3. Cercek A, et al. Mismatch Repair-Deficient Rectal Cancer and Resistance to Neoadjuvant
Chemotherapy. Clin Cancer Res. 2020 Jul 1;26(13):3271-3279. doi: 1158/1078-0432.
CCR-19-3728. Epub 2020 Mar 6. PMID: 32144135; PMCID: PMC7348681

4. Cercek, A., Lumish, M., Sinopoli, J. et al. (2022) ‘PD‑1 blockade in mismatch
repair-deficient, locally advanced rectal cancer’, New England Journal of Medicine,
386(25), pp. 2363-2376. Available at: https://www.nejm.org/doi/full/10.1056/NEJMoa2201445

5. Negro, S. et al. (2025) ‘Quality of life in rectal cancer treatments: a systematic
review’, Cancers, 17(14), 2310. Available at: https://www.mdpi.com/2072-6694/17/
14/2310

6. Neibart, S.S. et al. (2020) ‘Quality of life after radiotherapy for rectal cancer’,
Current Colorectal Cancer Reports, 16(1), pp. 1-10. Available at: https://pmc.ncbi.
nlm.nih.gov/articles/PMC7336840/

7. Cercek A, Roxburgh CS, Strombom P, et al. Adoption of Total Neoadjuvant Therapy
for Locally Advanced Rectal Cancer. JAMA Oncol. 2018;4(6):e180071. doi:10.1001/jamaoncol.
2018.0071

8. GSK press release issued 16 December 2024. Jemperli (dostarlimab) receives US
FDA Breakthrough Therapy Designation for locally advanced dMMR/MSI-H rectal cancer.
Available at https://www.gsk.com/en-gb/media/press-releases/jemperli-dostarlimab-
receives-us-fda-breakthrough-therapy-designation-for-locally-advanced-dmmrmsi-h-
rectal-cancer/

9. GSK press release issued 9 February 2023. US FDA Advisory Committee votes in 
support of trials designed to evaluate Jemperli (dostarlimab-gxly) as a potential
treatment for mismatch repair-deficient/microsatellite instability-high locally 
advanced rectal cancer. Available at https://www.gsk.com/en-gb/media/press-releases/
us-fda-advisory-committee-votes-in-support-of-trials-designed-to-evaluate-jemperli-
dostarlimab-gxly-as-a-potential-treatment-for-dmmrmsi-h-locally-advanced-rectal-
cancer/

10. Andre T, Berton D, Curigliano G, et al. Antitumor Activity and Safety of Dostarlimab
Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized
Controlled Trial. JAMA Netw Open. 2023;6(11):e2341165. doi:10.1001/jamanetworkopen.
2023.41165.

11. Le DT, et al. PD-1 blockade in tumors with mismatch repair deficiency. N Engl
J Med. 2015;372(26):2509-2520.

12. National Cancer Institute at the National Institutes of Health. Definition of
mismatch repair deficiency. Accessed August 2026. Available at: https://www.cancer.
gov/publications/dictionaries/cancer-terms/def/mismatch-repair-deficiency

13. JEMPERLI (dostarlimab) Summary of Product Characteristics. [GlaxoSmithKline](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l)(
Ireland) Limited. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/
jemperli. Accessed August 2026.

14. JEMPERLI (dostarlimab-gxly) prescribing information. GlaxoSmithKline. Available
at: https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/
Jemperli/pdf/JEMPERLI-PI-MG.PDF/. Accessed August 2026.

Share on:
